Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing

BOSTON, March 9, 2023 /PRNewswire/ — Allorion Therapeutics (“Allorion”), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a $50 million Series B financing round, co-led by INCE Capital and Qiming Venture…

Leave a Reply

Your email address will not be published. Required fields are marked *